Tagged with therapy

Opinion Pharmaceutical innovation is racing ahead of the US health system’s ability to adjust payment models, but innovative concepts are finally emerging. We will have to move beyond siloed thinking to establish them for the sake of getting patients sustainable access to a new wave of transformative cures, argues Ulrich Neumann.…

Rankings Below we present a list of the top 5 public biopharma companies that focus on developing RNA-based therapies. RNA interference (RNAi) is a natural mechanism which is present in living cells that selectively “turns off” specific gene’s expressions, thereby affecting the production of a specific protein that contributes to disease.…

Korea After failing to attain reimbursement for its Amyotrophic Lateral Sclerosis (ALS) treatment NEURONATA-R® in Korea, Corestem has its sights set on the US market and an Investigational New Drug (IND) approval from the FDA.   Dr Kyung Suk Kim, Corestem’s CEO, recently spoke to PharmaBoardroom to give an update on…

Korea Kyung Suk Kim, CEO of Corestem, the first company to receive approval for a stem cell therapy for Amyotrophic Lateral Sclerosis (ALS) in Korea, recounts the firm’s main achievements since her previous interview with PharmaBoardroom in 2018. Dr Kim unveils Corestem’s new strategy to prioritise the US market and offers…

Cell & Gene Therapy The cell and gene therapy market was valued at USD 6 billion in 2017 and is projected to exceed USD 35 billion in value by 2026. Moreover, these therapies stand to redefine medical paradigms by providing treatments for previously incurable diseases and usher in a new era of precise and…

Europe A full list of EMA ATMP approvals. Made with Visme Infographic Maker  

Cell & Gene Therapy A full list of the cell and gene therapy products approved by the US FDA. Made with Visme Infographic Maker  

Cell & Gene Therapy A full list of the regenerative medicine products that have been approved by the PMDA, Japan’s drug regulatory body.   Made with Visme Infographic Maker  

Korea Founder, CEO and CTO Dr Chae-Ok Yun introduces GeneMedicine, a pioneer of the oncolytic virus approach in gene therapy. Dr Yun outlines the significance of a recent capital injection, ongoing clinical trials, and the complementarity of oncolytic virus with other gene therapies such as CAR-T.   Oncolytic virus is not…

Cell & Gene Therapy Two years on from the introduction of Novartis Oncology’s CAR-T therapy to Europe, Emnuele Ostuni, the firm’s European head of cell and gene therapy, spoke to PharmaBoardroom about the pioneering product’s journey to market, what has been learnt along the way, and how his team has worked to assuage concerns…

Cell & Gene Therapy Emanuele Ostuni, Novartis Oncology’s head of cell and gene therapy for Europe, gives an overview of the introduction of the company’s CAR-T therapy to Europe, the work still to be done to get this product to more patients who need it across the continent, and the future of cell and…

Cell & Gene Therapy Deloitte’s Omkar Kawalekar, Hussain Mooraj, and Amit Agarwal examine the evolution and future of cell and gene therapy manufacturing and the areas in which biopharma firms need to invest in order to succeed in this emergent field.   Cell and gene therapies (CGT) are the next evolution of personalized health…